GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Enveric Biosciences
Enveric is a biotech company developing next-generation psychedelic drugs for the treatment of mental disorders. Its stock price is a venture capital bet on the legalization and medical use of these substances.
Share prices of companies in the market segment - Narco farm
Enveric Biosciences is a biopharmaceutical company developing next-generation psychedelic-based drugs for the treatment of mental disorders. We've classified it as a "Narco-Pharma" company. The chart below shows the dynamics of this new and promising pharmaceutical segment.
Broad Market Index - GURU.Markets
Enveric Biosciences is a biotech company developing psychedelic-based drugs for the treatment of mental disorders. It is a component of the GURU.Markets index. The chart below represents the market. See how this stock compares to the biotech sector.
Change in the price of a company, segment, and market as a whole per day
ENVB - Daily change in the company's share price Enveric Biosciences
For Enveric Biosciences, Inc., a company developing psychedelic-based drugs, daily volatility reflects sensitivity to clinical trial data. This metric is an important element in assessing risks in this innovative field.
Daily change in the price of a set of shares in a market segment - Narco farm
Enveric Biosciences is developing next-generation psychedelic drugs for the treatment of mental disorders. This is a highly speculative and volatile sector of biotech. The chart below reflects average fluctuations in this niche, serving as an indicator of risks and investor expectations.
Daily change in the price of a broad market stock, index - GURU.Markets
Enveric Biosciences is developing psychedelic-based drugs for the treatment of mental disorders. News of clinical trials in this cutting-edge field is causing sharp stock price movements, which, in turn, contribute to the overall "noise" and market dynamics.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Enveric Biosciences
Enveric Biosciences' year-to-date performance tells the story of its unique platform for developing new psychedelic drugs. Its 12-month market cap depends on progress in developing its modified molecules, which promise a therapeutic effect without hallucinations. Success could lead to a breakthrough in the treatment of depression and anxiety.
Annual dynamics of market capitalization of the market segment - Narco farm
Enveric, a biotech company developing psychedelic-based drugs, is completely independent of the sector and depends on news about clinical trials and legalization. Its stock price will reflect investors' speculative belief in the potential of this innovative approach.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Enveric Biosciences, which develops psychedelic-based drugs, represents one of the newest and most speculative niches in biotech. Its performance relative to the market is a clear bet on legislative changes and the success of clinical trials in this revolutionary field.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Enveric Biosciences
Enveric is a biopharmaceutical company developing psychedelic therapeutics. Its monthly growth is entirely dependent on progress in its preclinical and clinical programs. News about research results and regulatory changes are the main drivers.
Monthly dynamics of market capitalization of the market segment - Narco farm
The development of new psychedelic compounds for the treatment of mental disorders is a new frontier in pharmaceuticals. The dynamics of this biotech sector, shown in the graph, reflect its high research intensity and risks. Companies like Enveric Biosciences are conducting research in this area.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Enveric Biosciences is a biotech company developing psychedelic drugs for the treatment of mental disorders. This is a high-risk sector. Its stock price is entirely dependent on clinical trial results and regulatory changes, and has no connection to overall market trends.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Enveric Biosciences
Shares of Enveric Biosciences, which develops psychedelic drugs for the treatment of mental disorders, are extremely volatile. Weekly price movements depend entirely on news about preclinical and clinical trials. The chart below illustrates how short-term scientific developments and changing attitudes toward psychedelics influence the stock's price.
Weekly dynamics of market capitalization of the market segment - Narco farm
Enveric Biosciences is developing psychedelic drugs for the treatment of mental disorders. This is a revolutionary but high-risk field. The chart shows how much the company's stock price is influenced by regulatory changes and progress in clinical trials, rather than by general trends in the pharmaceutical industry.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Enveric Biosciences is researching psychedelics for medical use. This chart compares its weekly volatility with the market. It shows how much its stock moves based on news about clinical trials and regulatory changes, rather than general economic trends.
Market capitalization of the company, segment and market as a whole
ENVB - Market capitalization of the company Enveric Biosciences
Enveric Biosciences' market cap is a bet on its research into psychedelic compounds for the treatment of mental disorders. The company's preclinical valuation reflects investors' faith in a renaissance in psychedelic medicine. The chart illustrates the speculative nature and high risk inherent in this new wave of biotechnology.
ENVB - Share of the company's market capitalization Enveric Biosciences within the market segment - Narco farm
Enveric Biosciences's stake in the pharmaceutical industry is in the development of next-generation psychedelic drugs. The company modifies molecules such as psilocybin to create safer and more effective medications for mental disorders. Its strength lies in the potential of its scientific platform.
Market capitalization of the market segment - Narco farm
This chart is a barometer of the biotech sector exploring the therapeutic potential of psychedelics. Enveric Biosciences is one of the developers in this field. The dynamics on the chart reflect the hopes associated with the development of a new generation of drugs for the treatment of mental disorders.
Market capitalization of all companies included in a broad market index - GURU.Markets
Here's the market valuation of a biotech company exploring new psychedelic-based drugs. Enveric Biosciences' market cap reflects investors' faith in the potential of these compounds to treat mental disorders. The line shows how bold science is trying to carve out a stake in the future of psychiatry.
Book value capitalization of the company, segment and market as a whole
ENVB - Book value capitalization of the company Enveric Biosciences
The chart below shows the scientific foundation of Enveric Biosciences. Its line represents the value of the intellectual property for the company's portfolio of next-generation psychedelic compounds being developed to treat mental disorders. The dynamics reflect progress in the development of potential new drugs.
ENVB - Share of the company's book capitalization Enveric Biosciences within the market segment - Narco farm
Enveric Biosciences' core assets are its laboratories, where next-generation psychedelic drugs for the treatment of mental disorders are developed. The chart shows the company's share of this unique scientific infrastructure, which forms the physical basis for innovation in psychiatry.
Market segment balance sheet capitalization - Narco farm
In contrast to traditional pharmaceuticals, Enveric Biosciences is researching psychedelics. Its business is not currently capital-intensive. The chart shows the world of manufacturing, while Enveric is focused on R&D and intellectual property, laying the foundation for future drugs.
Book value of all companies included in the broad market index - GURU.Markets
Enveric Biosciences is developing next-generation psychedelic drugs for the treatment of mental disorders. The company's assets are not clinics, but rather chemical laboratories and intellectual property. The chart below illustrates the financial weight behind this attempt to create a "new psychiatry."
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Enveric Biosciences
Enveric Biosciences is a biopharmaceutical company developing psychedelic-based drugs. Its market capitalization is a speculative bet on the legalization and medical use of these substances for the treatment of mental disorders.
Market to book capitalization ratio in a market segment - Narco farm
Enveric Biosciences is a biotech company developing new psychedelic drugs for the treatment of mental disorders. Its value lies in its unique molecules and patents. This chart shows how its market valuation, based on expectations of success, is many times higher than its book value.
Market to book capitalization ratio for the market as a whole
Enveric Biosciences is a biotech company developing psychedelic drugs for the treatment of mental disorders. Their market valuation, as shown in this chart, is based on the potential of their intellectual property. Investors evaluate the likelihood of their drug candidates succeeding in a highly regulated environment.
Debts of the company, segment and market as a whole
ENVB - Company debts Enveric Biosciences
Enveric Biosciences, a biotech company developing next-generation psychedelic drugs, is using raised capital to fund its preclinical research. This chart shows how the company is spending its research funds to develop new molecules for the treatment of mental disorders.
Market segment debts - Narco farm
Enveric Biosciences is a biotech company developing next-generation psychedelic drugs for the treatment of mental disorders. This chart shows how its financial structure, with virtually no debt, reflects its early-stage research and reliance on equity capital to fund its innovative but high-risk programs.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Enveric Biosciences
Star Fashion Culture Holdings appears to operate in the fashion media and advertising space. This business is dependent on advertising budgets and trends. This chart shows the company's financial structure and how it uses capital to create content, organize events, and develop its media assets.
Market segment debt to market segment book capitalization - Narco farm
Enveric Biosciences is a biotech company developing novel psychedelic drugs for the treatment of mental disorders. This chart compares its debt load to the overall market capitalization of the pharmaceutical sector. It shows how the company funds its innovative research at the forefront of neuroscience.
Debt to book value of all companies in the market
Enveric Biosciences is developing psychedelic drugs for the treatment of mental disorders. This is a cutting-edge, yet controversial, area of pharmaceuticals that requires significant investment. This graph of total market debt shows investors' risk appetite, which is key to Enveric's ability to fund its long-term clinical programs.
P/E of the company, segment and market as a whole
P/E - Enveric Biosciences
For Enveric Biosciences, a biotech developing psychedelic-based drugs, the P/E ratio is irrelevant. The company has no profit. Its valuation on this chart is arbitrary. The real value is a speculative bet that its molecules will pass clinical trials.
P/E of the market segment - Narco farm
Enveric Biosciences is a biotech company developing a new generation of psychedelic drugs for the treatment of mental disorders such as anxiety and depression. The company aims to create molecules with an improved safety profile. This chart shows the average valuation for the psychopharmaceutical sector, reflecting investor expectations for a breakthrough in mental health treatment.
P/E of the market as a whole
Enveric Biosciences is a biotech company focused on developing a new generation of psychedelic drugs for the treatment of mental disorders. The company uses genetic engineering to create molecules with enhanced properties. This risk appetite chart helps understand how investors view the psychedelic medicine sector.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Enveric Biosciences
Enveric Biosciences is a biotech company developing new psychedelic-based drugs for the treatment of mental disorders. This chart reflects investor confidence in the potential of this new class of therapy. Future profits are entirely dependent on clinical trial results and regulatory changes.
%20P%2FE%20Enveric%20Biosciences&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Enveric-Biosciences&v=1772627776693 "Chart of the company's future (projected) P/E Enveric Biosciences")
Future (projected) P/E of the market segment - Narco farm
Enveric Biosciences is developing next-generation psychedelic drugs for the treatment of mental disorders. This chart is a barometer of market hopes. It compares investor confidence in the potential of its unique molecules and scientific approach with that of other companies in the resurgent psychedelic medicine sector.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Narco%20farm&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Narco-farm&v=1772627776701 "Future (projected) P/E graph of the market segment - Narco farm")
Future (projected) P/E of the market as a whole
Enveric Biosciences is developing next-generation psychedelic drugs for the treatment of mental disorders. The company's future depends on regulatory changes and successful clinical trials. This chart, showing overall sentiment, reflects the investor appetite for risk required to fund research in such an innovative yet controversial field of medicine.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772627776713 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Enveric Biosciences
Enveric Biosciences is a biotech company developing novel psychedelic drugs for the treatment of mental disorders. Its financial profile is typical for an early-stage company: high research costs and no revenue. This chart illustrates the investment in clinical trials for potentially breakthrough treatments.
Profit of companies in the market segment - Narco farm
Enveric Biosciences is developing next-generation psychedelic drugs for the treatment of mental disorders. This chart, showing overall profitability in the pharmaceutical sector, reflects the resurgence of interest in psychedelics. Enveric's success in developing safe and effective drugs could open a new multibillion-dollar market and radically change the industry.
Overall market profit
Enveric Biosciences develops psychedelic drugs for the treatment of mental disorders. This is one of the most cutting-edge and controversial areas in modern pharmacology. The company's value depends entirely on scientific discoveries, legislative changes, and the ability to demonstrate the therapeutic benefits of these substances.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Enveric Biosciences
Enveric Biosciences is a biotechnology company developing next-generation psychedelic drugs for the treatment of mental disorders. The future revenue projections presented here are speculative and reflect expectations for clinical trials and potential changes in the regulation of psychedelic medicine.
%20profit%20of%20the%20company%20Enveric%20Biosciences&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Enveric-Biosciences&v=1772627776725 "Graph of future (projected) profit of the company Enveric Biosciences")
Future (predicted) profit of companies in the market segment - Narco farm
Enveric Biosciences is developing next-generation psychedelic drugs for the treatment of mental disorders. This chart shows revenue projections for the psychopharmacology segment. It allows one to assess how the company's innovative research in this controversial but promising field compares to the overall expectations of a revolution in the treatment of depression and anxiety.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Narco%20farm&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Narco-farm&v=1772627776729 "Graph of future (predicted) profits of companies in a market segment - Narco farm")
Future (predicted) profit of the market as a whole
Enveric Biosciences is developing psychedelic drugs for the treatment of mental disorders. This is a cutting-edge but risky field. This chart is important because it reflects investor willingness to fund such innovative ventures. During periods of growth and stability, capital is more willing to flow into new pharmaceutical sectors, which is critical for Enveric.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772627776730 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Enveric Biosciences
Enveric Biosciences is developing next-generation psychedelic drugs for the treatment of mental disorders. For a preclinical company, this graph, which correlates market capitalization with no revenue, reflects pure potential. It demonstrates investors' faith in the renaissance of psychedelic medicine and the company's scientific approach.
P/S market segment - Narco farm
Enveric Biosciences is developing next-generation psychedelic drugs for the treatment of mental disorders such as anxiety and depression. The company strives to create safer and more effective therapies. This chart reflects the market's willingness to pay for biotech revenue, highlighting expectations for the development of psychedelic medicine and Enveric's role in it.
P/S of the market as a whole
Enveric Biosciences is a biotech company developing next-generation psychedelic drugs for the treatment of mental disorders. This chart, showing the average market revenue valuation, emphasizes that the valuation of such companies is based not on current revenue, but on the future potential of their research.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Enveric Biosciences
Enveric Biosciences is developing new psychedelic-based drugs for the treatment of mental disorders. This chart shows investor estimates of its potential future revenue. It reflects the market's belief in the coming revolution in psychiatry and the commercial potential of its innovative therapeutic approaches.
%20P%2FS%20Enveric%20Biosciences&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Enveric-Biosciences&v=1772627776767 "The graph of the company's future (projected) P/S Enveric Biosciences")
Future (projected) P/S of the market segment - Narco farm
Enveric Biosciences is a biotech company developing new psychedelic drugs for the treatment of mental disorders. The chart shows the average future sales estimate for the cannabis sector. It allows one to assess how the market views Enveric's scientific developments and its potential to create a new class of drugs compared to other players in the field.
%20P%2FS%20market%20segment%20graph%20-%20Narco%20farm&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Narco-farm&v=1772627776772 "Future (projected) P/S market segment graph - Narco farm")
Future (projected) P/S of the market as a whole
Enveric Biosciences (ENVB) is developing next-generation psychedelic drugs for the treatment of mental disorders. Their potential lies in scientific breakthroughs and changing perspectives on therapy. This graph of general economic expectations is irrelevant to their mission to create innovative medications for mental health.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772627776775 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Enveric Biosciences
Enveric Biosciences is a biotech company developing a new generation of psychedelic drugs. Being in the preclinical stage, it has no sales revenue. Its financial history is one of investing in science. The graph reflects future revenue from licensing its candidate molecules to major pharmaceutical partners.
Sales of companies in the market segment - Narco farm
Enveric Biosciences is a biotech company focused on developing a new generation of psychedelic drugs for the treatment of mental disorders. Being in the preclinical stage, it does not yet have revenue. Its valuation is based on the potential of its scientific developments in this cutting-edge field of medicine.
Overall market sales
Enveric Biosciences is a biotech company developing new psychedelic drugs for the treatment of mental disorders. The company's success depends on scientific breakthroughs and regulatory changes. This chart, reflecting the overall state of the economy, influences investor appetite for high-risk but potentially revolutionary areas such as psychedelic therapy development.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Enveric Biosciences
Enveric Biosciences is a biotechnology company developing next-generation psychedelic drugs for the treatment of mental disorders. Future revenue depends on the success of its preclinical and clinical programs. This chart reflects analysts' long-term expectations for the psychedelic medicine market.
%20sales%20of%20the%20company%20Enveric%20Biosciences&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Enveric-Biosciences&v=1772627776801 "Schedule of future (projected) sales of the company Enveric Biosciences")
Future (projected) sales of companies in the market segment - Narco farm
Enveric Biosciences is a biotech company developing next-generation psychedelic drugs for the treatment of mental disorders. This chart shows the outlook for the cannabis and psychedelic sectors. It reflects the growing recognition of the therapeutic potential of these compounds, which is driving Enveric's R&D efforts.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Narco%20farm&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Narco-farm&v=1772627776809 "Schedule of future (projected) sales of companies in the market segment - Narco farm")
Future (projected) sales of the market as a whole
This graph, reflecting investor willingness to fund cutting-edge research, is important for Enveric Biosciences. The company is developing psychedelic drugs for the treatment of mental disorders. Raising capital for this innovative but risky field is highly dependent on overall risk appetite in the markets.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772627776820 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Enveric Biosciences
Enveric Biosciences is focused on the discovery and development of next-generation psychedelic drugs for the treatment of mental disorders. This schedule reflects the intensive preclinical research stage. Future profitability depends entirely on the successful development of safe and effective drugs that can undergo extensive clinical trials.
Market segment marginality - Narco farm
Enveric Biosciences is a biotech company developing next-generation psychedelic drugs for the treatment of mental disorders. Profitability depends on the success of clinical trials and changes in the regulatory environment. This chart shows the average profitability in the pharmaceutical industry, providing context for assessing Enveric's potential in this innovative field.
Market marginality as a whole
Enveric Biosciences is developing psychedelic drugs for the treatment of mental disorders. This is a cutting-edge but risky field, entirely dependent on funding and regulatory changes. This chart shows the overall risk appetite of investors, which determines whether the market has the capital to support such innovative yet long-term medical research.
Employees in the company, segment and market as a whole
Number of employees in the company Enveric Biosciences
Enveric Biosciences is developing next-generation psychedelic drugs for the treatment of mental disorders. This chart reflects the size of the scientific team conducting preclinical studies. A small and focused team is typical for early-stage biotech companies, whose primary goal is to prove the viability of their scientific platform.
Share of the company's employees Enveric Biosciences within the market segment - Narco farm
Enveric Biosciences is developing next-generation psychedelic drugs for the treatment of mental disorders such as anxiety and depression. This chart shows the percentage of all scientists in this revolutionary field that the company employs. It's an indicator of its research programs and potential for creating innovative therapies.
Number of employees in the market segment - Narco farm
Enveric Biosciences is a biotech company developing next-generation psychedelic drugs for the treatment of mental disorders. This chart, reflecting employment in the psychopharmaceutical sector, is important. The growing number of scientists in this field indicates a renaissance in psychedelic research and the search for breakthrough treatments for depression and anxiety disorders.
Number of employees in the market as a whole
Enveric Biosciences is developing psychedelic drugs for the treatment of mental disorders. This cutting-edge field of medicine requires significant funding. This overall employment chart reflects the health of the economy, which is essential for biotech investment. Steady growth attracts capital to risky but potentially breakthrough areas of pharmaceuticals.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Enveric Biosciences (ENVB)
Enveric Biosciences is a biotech company developing new psychedelic drugs for the treatment of central nervous system disorders. This chart shows the pure valuation of its "intellectual capital." The company has no manufacturing facilities; its value comes from its team of scientists and a portfolio of patents for new molecules. The market factors in the potential of future drugs.
%20of%20the%20company%20Enveric%20Biosciences%20(ENVB)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Enveric-Biosciences-ENVB&v=1772627776859 "Chart of market capitalization per employee (in thousands of dollars) of the company Enveric Biosciences (ENVB)")
Market capitalization per employee (in thousands of dollars) in the market segment - Narco farm
Enveric Biosciences is developing psychedelic drugs for the treatment of mental disorders. This is a cutting-edge field of biotechnology, where market value depends entirely on the success of the research. The chart shows the high valuation the market can place on the work of a small team of scientists whose intellectual property has the potential to transform an entire field of medicine.
%20by%20market%20segment%20-%20Narco%20farm&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Narco-farm&v=1772627776859 "Market capitalization per employee (in thousands of dollars) by market segment - Narco farm")
Market capitalization per employee (in thousands of dollars) for the overall market
Enveric Biosciences develops psychedelic drugs for the treatment of mental disorders. Its market cap in this cutting-edge field is based on its potential to transform approaches to therapy. This metric reflects a huge market value per employee, as investors are betting on the scientific breakthroughs of a small team of researchers.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772627776860 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Enveric Biosciences (ENVB)
Enveric Biosciences is a biotech company focused on developing next-generation psychedelic drugs (psilocybin derivatives) for the treatment of mental disorders. This is pure R&D. This chart reflects the company's "burn rate": it shows how much the company spends (negative profit) on each scientist working on the creation and clinical testing of these innovative molecules.
%20Chart%20Enveric%20Biosciences%20(ENVB)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Enveric-Biosciences-ENVB&v=1772627776869 "Company Profit Per Employee (in thousands of dollars) Chart Enveric Biosciences (ENVB)")
Profit per employee (in thousands of dollars) in the market segment - Narco farm
Enveric Biosciences is developing psychedelic drugs for the treatment of mental disorders. Like many biotech companies in the research stage, Enveric incurs significant R&D expenses. This chart demonstrates the efficiency of resource management. Potential profitability depends on successful clinical trials and commercialization of the developments.
%20in%20the%20market%20segment%20-%20Narco%20farm&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Narco-farm&v=1772627776889 "Chart of profit per employee (in thousands of dollars) in the market segment - Narco farm")
Profit per employee (in thousands of dollars) for the market as a whole
Enveric Biosciences (ENVB) is a biotech company developing novel psychedelic drugs (based on psilocybin and DMT) for the treatment of mental disorders. It is a preclinical R&D company and is not profitable. This figure reflects the high cost of investing in a single scientist working in the cutting-edge but risky field of "psychedelic pharma."
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772627776897 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Enveric Biosciences (ENVB)
Enveric Biosciences is developing psychedelic drugs for the treatment of mental disorders. For an early-stage biotech company, this timeline is an important starting point. Success in clinical trials could transform a small team's research into a blockbuster with massive revenue.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Enveric-Biosciences-ENVB&v=1772627776898 "Sales chart per company employee Enveric Biosciences (ENVB)")
Sales per employee in the market segment - Narco farm
Enveric Biosciences is a biotech company developing next-generation psychedelic-based drugs (DMT, psilocybin) for the treatment of mental disorders. This is an R&D company. This graph reflects their clinical stage. The productivity of their research team is measured not by current sales, but by the creation and patenting of new molecules.
Sales per employee for the market as a whole
Intellia Therapeutics (NTLA) is a pioneer in CRISPR genome editing, developing drugs to treat genetic diseases. The company is in the clinical stage, meaning its revenue (if any) comes from partnerships rather than sales. This chart illustrates the economics of R&D, showing how much capital the company is investing in its world-class scientists to create therapies of the future.
Short shares by company, segment and market as a whole
Shares shorted by company Enveric Biosciences (ENVB)
Enveric (ENVB) is another biotech company operating in the psychedelic sector, developing new molecules based on these compounds. This chart shows the volume of short positions. Shorting is a bet that the company is burning through money on R&D, which has an extremely low chance of commercial and regulatory success.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Enveric-Biosciences-ENVB&v=1772627776944 "Short Shares Chart for the Company Enveric Biosciences (ENVB)")
Shares shorted by market segment - Narco farm
Enveric (ENVB) is a biotech company developing psychedelic drugs (based on psilocybin) for the treatment of mental disorders. The chart below shows the overall short position on the psychedelics sector. It demonstrates how skeptical investors are of this emerging industry, its regulations, and its timeline.
Shares shorted by the overall market
Enveric Biosciences develops psychedelic-based drugs (psilocybin, DMT) for the treatment of mental disorders. This is a highly speculative sector. This chart reflects the general fear. When investors are pessimistic, they flee sectors with legal uncertainty. ENVB shares, dependent on legalization and expensive trials, are the first to be sold off.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Enveric Biosciences (ENVB)
This chart for Enveric is a barometer of the hype surrounding "second-generation" psychedelics. The company is developing new molecules (psilocybin analogs), but without the hallucinogenic effect, for the treatment of depression. "Overheating" (above 70) occurs due to positive preclinical data. The highest risk of failure and long road to approval lead to "oversold" status.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Enveric-Biosciences-ENVB&v=1772627776965 "RSI 14 indicator chart for the company's stock Enveric Biosciences (ENVB)")
RSI 14 Market Segment - Narco farm
Enveric Biosciences is a biotech company engaged in R&D in the field of psychedelics. They are developing and patenting new molecules (psilocybin and MDMA analogs) for the treatment of central nervous system disorders. This chart reflects the overall sentiment in the volatile psychedelic pharmaceutical sector. It helps assess whether the entire segment is overheated or oversold.
RSI 14 for the overall market
Enveric Biosciences (ENVB) is researching psychedelics for the treatment of mental disorders. This line of biotechnology requires significant capital and a high risk appetite. This chart shows the overall market "temperature." When investors are euphoric (overbought), they are willing to fund bold ideas. In moments of panic (oversold), access to capital for companies like ENVB is virtually cut off.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast ENVB (Enveric Biosciences)
Enveric (ENVB) is developing "next-generation molecules" based on psychedelics (DMT, psilocybin) for the treatment of mental disorders. This chart shows the average target price. It reflects analysts' speculative assessment of this cutting-edge but risky scientific platform and its chances of clinical success.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-ENVB-Enveric-Biosciences&v=1772627776983 "A chart showing analyst consensus forecasts for the expected stock price. ENVB (Enveric Biosciences)")
The difference between the consensus estimate and the actual stock price ENVB (Enveric Biosciences)
Enveric Biosciences (ENVB) is a biotech company developing a new generation of psychedelic drugs for the treatment of mental disorders (depression, PTSD). This chart illustrates the analyst community's opinion on the company's future. It measures the distance between the stock price and the target, reflecting their outlook on this risky R&D area.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-ENVB-Enveric-Biosciences&v=1772627776987 "A chart showing the difference between the consensus forecast and the actual stock price. ENVB (Enveric Biosciences)")
Analyst consensus forecast for stock prices by market segment - Narco farm
Enveric Biosciences is a biotech company that discovers and modifies psychedelic (psilocybin, DMT) and cannabinoid compounds for the treatment of mental disorders. This chart shows general expectations for the drug farm sector. It reflects whether experts believe in a "psychedelic renaissance" in medicine.
Analysts' consensus forecast for the overall market share price
Enveric Biosciences (ENVB) is a biopharmaceutical company working at the forefront of psychiatry. They are developing a new generation of "safe" psychedelic drugs for the treatment of depression and PTSD. This chart shows the overall risk appetite, reflecting the market's willingness to fund breakthrough but regulatory-challenging areas of medicine.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Enveric Biosciences
Enveric Biosciences is a pioneer in psychedelic biotechnology. They don't sell mushrooms, but rather develop new, patented molecules (based on psilocybin and DMT) for the treatment of severe depression and anxiety. This chart is a barometer of the psychedelic renaissance. It reflects their progress in R&D, their patent portfolio, and the market's confidence in the FDA's approval of these drugs.
AKIMA Market Segment Index - Narco farm
Enveric Biosciences occupies a unique niche: they develop new psychedelic drugs (drug farm) to treat severe mental health conditions, such as cancer-related anxiety. This chart compares their composite index to the sector, allowing investors to assess how their innovative, yet risky, approach outperforms their competitors.
The AKIM Index for the overall market
Enveric Biosciences is a biotech company developing next-generation psychedelic molecules for the treatment of mental disorders (anxiety, depression). This chart, which reflects the market average, provides a macro backdrop. It helps assess how this speculative scientific story fits into the context of overall economic trends and interest in psychedelics.
